Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27843091 | 0.81 | LMNA (0.50) | GABRA1GABRB1LMNACA1CA2 | |
| SCHEMBL2530469 | 0.78 | ALDH1A1 (0.50) | GABRA1LMNAGABRB2CYP1A2CYP3A4 | |
| SCHEMBL3236809 | 0.76 | DHFR (0.36) | GABRA1LMNACA1CA2GABRB2 | |
| SCHEMBL9743581 | 0.76 | GABRA1 (0.52) | GABRA1GABRB1LMNACA1CA2 | |
| SCHEMBL3683159 | 0.76 | GABRA1 (0.48) | GABRA1GABRB1LMNACA1CA2 | |
| SCHEMBL27727127 | 0.75 | GABRA1 (0.47) | GABRA1GABRB1LMNACA1CA2 | |
| SCHEMBL9743764 | 0.75 | GABRA1 (0.61) | GABRA1GABRB1LMNACA1CA2 | |
| SCHEMBL23198665 | 0.74 | GABRA1 (0.62) | GABRA1GABRB1LMNACA1CA2 | |
| SCHEMBL30336636 | 0.74 | GABRA1 (0.62) | GABRA1GABRB1LMNACA1CA2 | |
| SCHEMBL10457926 | 0.73 | DHFR (0.44) | GABRA1GABRB1LMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329452-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2921228-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-9061959-B2 | Method for manufacturing optically active menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| EP-2647616-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8329931-B2 | Organoaluminum compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20110295031-A1 | ORGANOALUMINUM COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-2390001-A1 | Organoaluminium compounds and their use as catalysts in the selective cyclisation of citronellal to isopulegol | Takasago International Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110256013-A1 | METHOD FOR PRODUCING REGENERATED TARGET | TANAKA HOLDINGS CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329452-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ISOPULEGOL AND OPTICALLY ACTIVE MENTHOL | ACSL3, ACSL6, ALOX5 | GABRA1 2593/4885GABRB1 3042/4885LMNA 1516/4885 |
| US-20110295031-A1 | ORGANOALUMINUM COMPOUND | CDC5L, ACSL3, MSMO1 | GABRA1 2612/4885GABRB1 2185/4885LMNA 1737/4885 |
| US-20130253228-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | MSMO1, GGPS1, MAN1B1 | GABRA1 1977/4885GABRB1 2210/4885LMNA 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.